Phio Pharmaceuticals Corp (NASDAQ:PHIO)’s traded shares stood at 84045.0 during the last session, with the company’s beta value hitting 0.85. At the close of trading, the stock’s price was $2.4, to imply a decrease of -3.23% or -$0.08 in intraday trading. The PHIO share’s 52-week high remains $9.79, putting it -307.92% down since that peak but still an impressive 59.58% since price per share fell to its 52-week low of $0.97. The company has a valuation of $11.52M, with an average of 0.24 million shares in intraday trading volume over the past 10 days and average of 3.36 million shares over the past 3 months.
Phio Pharmaceuticals Corp (NASDAQ:PHIO) trade information
After registering a -3.23% downside in the last session, Phio Pharmaceuticals Corp (PHIO) has traded red over the past five days. The 5-day price performance for the stock is 8.60%, and 14.83% over 30 days. With these gigs, the year-to-date price performance is -60.30%. Short interest in Phio Pharmaceuticals Corp (NASDAQ:PHIO) saw shorts transact 0.24 million shares and set a 0.35 days time to cover.
Phio Pharmaceuticals Corp (PHIO) estimates and forecasts
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 66.30% for the past 5-year period. While 2025 is set for a 82.60% return in earnings, projections for the next 5 years are at 64.39% annually.
PHIO Dividends
Phio Pharmaceuticals Corp has its next earnings report out on 2025-Mar-31. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Phio Pharmaceuticals Corp (NASDAQ:PHIO)’s Major holders
Phio Pharmaceuticals Corp insiders hold 0.40% of total outstanding shares, with institutional holders owning 15.77% of the shares at 15.83% float percentage. In total, 15.77% institutions holds shares in the company.
We also have Delaware Group Equity Funds IV-Macquarie Healthcare Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Phio Pharmaceuticals Corp (PHIO) shares. Going by data provided on Mar 31, 2025, Delaware Group Equity Funds IV-Macquarie Healthcare Fund holds roughly 50.0 shares. This is just over 1.04% of the total shares, with a market valuation of $0.12 million. Data from the same date shows that the other fund manager holds a little less at 28.16, or 0.59% of the shares, all valued at about 67581.0.
